Financial Results for the quarter ended June 30, 2026

Aug ust 12, 2026 BSE Limited National Stock Exchange of India Ltd Department of Corporate Relationship Department of Corporate Services 1st Floor, New Trade Ring, Rotunda Building Exchange Plaza, 5th Floor, Phiroze Jeejeebhoy Towers C-1, Block G, Bandra Kurla Complex, Dalal Street, Mumbai- 400001 Bandra (E), Mumbai – 400 051 Scrip Code: 524742 S c r i p C o d e : C A P L I P O I N T . Dear Sir/Madam, Sub: Outcome of Board Meeting Further to our intimation dated July 29, 2026, we wish to inform you that the Board of Directors, at its meeting held today, i.e. August 12, 2026, has, inter-alia, approved the following: 1. Approved the unaudited standalone and consolidated financial results (Annexure 1) and the Limited Review Report of the Company as per Indian Accounting Standards for the quarter ended June 30, 2026 (Annexure 4). We also enclose a Press Release on the results (Annexure 2) and an investor presentation (Annexure 3). 2. Recommended a Final Dividend of Rs.4/- (200%) per equity share of Rs.2/- each for the financial year ended March 31, 2026. The said dividend, if approved at the forthcoming Annual General Meeting (“AGM”), shall be paid on or before October 24, 2026. 3. Approved the Record Date for determining the eligibility of the Shareholders for the purpose of Final Dividend. The same shall be communicated to the Stock Exchanges separately as per the timelines specified under the Listing Regulations. 4. Approved the re-appointment of Dr. Sridhar Ganesan (DIN: 06819026) as the Managing Director of the Company for a further period of two (2) years, with effect from August 25, 2026, to August 24, 2028, subject to the approval of the Shareholders at the forthcoming Annual General Meeting. 5. Approved the appointment of Mr. D. Muralidharan (DIN: 08301904) as the Whole-Time Director of the Company for a period of two (2) years, with effect from August 12, 2026, to August 11, 2028, subject to the approval of the Shareholders at the forthcoming Annual General Meeting. Mr. D. Muralidharan shall continue as the Chief Financial Officer of the Company in addition to him being designated the Whole Time Director. 6. Approved the convening of the 35th Annual General Meeting of the Company on Friday, September 25, 2026, through Video Conferencing / Other Audio-Visual means. The meeting commenced at 10.45 A.M. and concluded at 01.25 P.M. The details of the change in Directors, in accordance with Regulation 30 of SEBI Listing Regulations read with SEBI Master Circular HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, is enclosed (Annexure 5). Kindly take the same on your records. Sincerely Yours For Caplin Point Laboratories Limited Venkatram G General Counsel & Company Secretary Membership No. A23989 Encl: A/a ANNEXURE -1 CAPLIN POINT LABORATORIES LIMITED STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2026 Quarter Ended Vear Ended 30.06.2026 31.03.2026 30.06.2025 31.03.2026 Particulars (1) (2) (3) (4) {Unaudited) (Audited) (Unaudited) (Audited) , in Crores Income I Revenue from operations 202.95 191.36 182.57 738.33 II Other income 62.79 72.39 32.03 195.37 Ill Total Income (1+11) 265.74 263.75 214.60 933.70 -- - IV Expenses a. Cost of materials consumed 42.12 45.80 38.62 158.82 b. Purchase of traded goods 27.42 24.67 13.18 82.5-1 c. Changes in inventories of finished goods, stock in (11.38) (14.89) 6.27 (12.37) trade and work in pro11:ress d. Employee benefits expense 13.73 13.15 9.63 47.72 e. Finance costs 0.05 0.05 0.04 0.20 1~ - -- f. Depreciation & Amortisation Expense 6.56 6.90 6.14 25.43 g. Other Expenses 36.65 39.04 28.26 123.87 Total Expenses 115.15 114.72 102.14 426.18 V Profit before exceptional items and Tax (Ill-IV) 150.59 149.03 112.46 507.52 VI Exceptional items - - - - VII Profit Before Tax (V-VI) 150.59 149.03 112.46 507.52 -- -- VIII Tax Expenses - -- - - -- (1) CurrentTax 28.76 26.45 26.91 109.49 - -- (2} Deferred Tax 1.45 1.77 (0.34) 1.45 Total Tax Expenses 30.21 28.22 26.57 110.94 IX Net Profit for the period (VII-VIII) 120.38 120.81 85.89 396.58 Other Comprehensive Income/ (Loss) - Net of Tax A. Items that will not be re-classified to profit or loss - i) Remeasurements of Defined Benefit Plc1n - (0.17) - (0.09) ii) Income tax relating to these items - 0.04 - 0.02 XI Total Comprehensive Income For The Period (IX-+-X) 120.38 120.68 85.89 396.51 Paid up Equity Share Capital (Face value of shares of Rs Xll 15.20 15.20 15.20 15.20 2/-each) XIII Other equity 2,035.30 Earnings Per Share (EPS) of Face value Rs 2/-per Equity share* (a) Basic (in Rupees) 15.84 15.89 1 -1.3 -0 - 52.17 (b) Diluted (in Rupees) - 15.79 15.85 11.26 52.02 *{Not *{Not *(Not *(Annualised) Annualised) Annualised) Annualised) See Accompanying notes to Financial Results CAPLIN POINT LABORATORIES LIMITED St~ndalone Notes: 1) The above Unaudited Standalone financial Results for the Quarter ended June 30, 2026 were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on August 12, 2026 and reviewed by the Statutory Auditors. 2) The Unaudited Standalone financial results of the Company have been prepared in accordance with the Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder ("Ind AS") and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. 3) The Company is engaged in the sole activity of carrying on the business of "Pharmaceutical Formulations" and therefore no separate segment reporting is applicable to the Company. 4) Other Income and Profit Before Tax includes: if In Crores Quarter Ended Year Ended Particulars 30.06.2026 31.03.2026 30.06.2025 31.03.2026 Dividend from wholly owned subsidiary Caplin Point Far East Limited 28.90 30.55 8.12 62.30 5) Details of number of shares allotted under Employee Stock Option Plan (ESOP): Number of Shares Quarter Ended Year Ended Particulars 30.06.2026 31.03.2026 30.06.2025 31.03.2026 Shares Alloted under Emptoyee Stock Option Plan (ESOP) - - - - Total Number of Equity Shares of the Company 7,60, 11,696 7,60, 11,696 7,60,11,696 7,60,11,696 6) The Board of Directors at their meeting held on 14th May, 2026 declared an interim dividend of N.00 (Rs. Four Only) per equity share (200 %) for the financial year 2025-26 and was paid to the shareholders on 8th June 2026. The Board of Directors at their meeting held today have recommended a final dividend of 1{ ...4 .-.. t- per equity share (f;?-!?!liio) for the financial year 2025-26 which is subject to approval of the Shareholders in the ensuing Annual General Meeting of the Company. The total dividend for the financial year 2025-26 including the final dividend {subject to the approval of the Shareholders at the ensuing Annual General Meeting) will be c K .1-per equity share (iiM>lo) of the face value of 1{ 2 each. 7) Previous periods' figures have been regrouped/ reclassified to be in conformity with current period's classification/ disclosure, wherever necessary. Place: Chennai Dr. Sridhar Ganesan Date: August 12, 2026 Managing Director CAPLIN POINT LABORATORIES LIMITED STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2026 Quarter Ended Year Ended 30.06.2026 31.03.2026 30.06.2025 31.03.2026 Particulars (1) (2) (3) (4) (Unaudited) (Audited) (Unaudited) (Audited) , in Crores - Income - I Revenue from operations 610.36 600.16 510.22 2,187.19 II Other income 33.55 28.36 23.14 115.54 Ill Total Income (1+11) 643.91 628.52 533.36 2,302.73 IV Expenses a. Cost of materials consumed 107.06 102.11 90.20 357.20 b. Purchase of traded goods 196.36 - 209.02 96.81 572.20 c. Changes in inventories of finished goods, stock in trade and work (58.22) (66.13) 8.23 (63.72) in progress d. Employee benefits expense 54.13 52.62 43.16 199.15 e. Finance costs 0.18 [Showing first 8,000 characters — download PDF for full document]